HPV vaccination in High-Income Countries (HIC)
Main objective. To estimate, using HPV-ADVISE, the effectiveness and cost-effectiveness of different HPV vaccination and cervical screening strategies to reduce the burden of HPV-related diseases and health inequalities in Canada and the US.
Specific objectives are to:
- Use HPV-ADVISE to identify optimal HPV vaccination and cervical screening policies to achieve cervical cancer elimination in North America
- Use HPV-ADVSE to estimate the potential effectiveness of reducing the number of HPV vaccine doses on HPV-related outcomes in high income countries
- Use HPV-ADVISE to identify biases in epidemiological studies of HPV vaccination effectiveness and identify optimal study designs to improve validity and precision
Ongoing activities. We are currently addressing the 3 public health questions described above. Furthermore, we are continuously refining HPV-ADVISE by confronting the model to post-vaccination data and predictions from other models.
Partners. INSPQ, PHO, BC CDC, CDC, PHE, Program for Appropriate Technology in Health (PATH), Compute Canada
HPV vaccination in Low-and-Middle-Income Countries (LMIC)
Main objective. To estimate, using HPV-ADVISE LMIC, the effectiveness and cost-effectiveness of different HPV vaccination and cervical screening strategies to reduce the burden of HPV-related diseases in LMIC, as well as identify strategies that can lead to cervical cancer elimination.
Specific objectives are to:
- Use HPV-ADVISE LMIC to examine the effectiveness and cost-effectiveness of HPV vaccination strategies in different LMICs such as Tanzania, and Cuba (e.g., girls-only or gender-neutral vaccination, 1 or 2 doses, 2- or 9-valent vaccine, single or multiple age cohorts)
- Use HPV-ADVISE LMIC to identify optimal HPV vaccination strategies in the context of HPV vaccine supply constraints (e.g., strategies that maximize the number of cervical cancer cases prevented for a fixed amount of available doses worldwide)
- Use HPV-ADVISE LMIC to estimate the cost-effectiveness of different cervical cancer elimination strategies in 78 LMIC
- Develop an HIV/HPV transmission model based on HPV-ADVISE (HPV/HIV-ADVISE).
Ongoing activities. In collaboration with our international partners, our core efforts are currently focussed on examining the effectiveness/cost-effectiveness of different HPV vaccination strategies in LMIC in the context of vaccine supply constraints and call for action to eliminate cervical cancer. We are also working in close collaboration with the WHO and researchers/decision makers from different LMIC to refine our models and answer country-specific questions. As part of the WHO Cervical Cancer Elimination Modeling Consortium, we are using HPV-ADVISE LMIC to identify the most cost-effective vaccination and screening strategies that could lead to cervical cancer elimination. As part of the Single-dose HPV vaccine evaluation consortium, we are continuing our modeling work to guide global decision about 1-dose HPV vaccination and extended schedules (e.g., 5 years between the first and second dose). Finally, we are including HIV in HPV-ADVISE to examine the potential for cervical cancer elimination in high HIV prevalence countries.
Partners. WHO, International Agency for Research on Cancer (IARC), PATH, Compute Canada